Striverdi Respimat (olodaterol) / Boehringer Ingelheim - LARVOL DELTA

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD. (PubMed, Pharmacol Res Perspect) - "Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol), long (formoterol, salmeterol), and ultra-long-acting (indacaterol, olodaterol, vilanterol) β2-agonists. Comparison with other β-ligands suggests that affinity and duration could both be improved further. However, given the very wide range of molecular pharmacological properties of β-agonists that are clinically effective and widely used, non-pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) may be as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2-agonists themselves."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of drug permeability using a small airway microphysiological system. (PubMed, Front Pharmacol) - "Insignificant nonspecific binding to the MPS was observed with albuterol sulfate, formoterol fumarate, and olodaterol hydrochloride (HCl), while fluticasone furoate showed significant nonspecific binding as only 6%-44% of the drug was recovered at 30 and 120 min, respectively. Taken together, the small airway MPS recapitulated relevant cell types and many morphological features in the lung. The apparent permeabilities measured indicated that albuterol sulfate and formoterol fumarate would be categorized as highly permeable, while olodaterol HCl would be categorized as a low permeable drug."

Journal

The Development of One New Normal Phase Liquid Chromatography Method and Thermodynamic Investigation of Olodaterol Hydrochloride Enantiomer. (PubMed, Chirality) - "Thereby, the proposed method was demonstrated to be suitable for the determination of enantiomer in olodaterol hydrochloride bulk drug and drug product. Besides, the thermodynamic parameters were evaluated on the basis of Van't Hoff plots that was used to explain correlative chiral recognition mechanisms with the chiral stationary phase."

Journal

Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients (PRNewswire) - "Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. The program applies to all Boehringer Ingelheim inhalers, including: Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray. Spiriva HandiHaler (tiotropium bromide inhalation powder). Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray. Spiriva Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray. Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Striverdi Respimat (olodaterol) Inhalation Spray."

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

Clinically Relevant β2-agonists Induce and Augment Rhinovirus-induction of Asthma-relevant Pro-inflammatory Mediators in Human Bronchial Epithelial Cells (ATS 2024) - " BEAS-2B BECs were stimulated with SABAs (fenoterol, salbutamol), LABAs (formoterol, salmeterol), ultra-LABAs (indacaterol, olodaterol, vilanterol), short-acting (ipratropium) or long-acting (tiotropium, aclidinium, umeclidinium) muscarinic antagonists, at concentrations 0. β2-agonists upregulate BEC production of asthma-relevant pro-inflammatory mediators, while muscarinic antagonists do not. β2-agonists also augment RV-induction of disease-relevant mediators. Corticosteroid co-administration abolishes these pro-inflammatory effects."

Clinical • Late-breaking abstract • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • BDNF • IL6

LAMA improve tissue oxygenation more than LABA in patients with COPD. (PubMed, J Appl Physiol (1985)) - "Objectives To compare the action of long-acting ß2-agonists (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium) on tissue oxygenation in COPD, considering their impact on proximal and peripheral ventilation as well as lung perfusion...The mechanisms involved may differ between both drugs: LABA increased peripheral ventilation while LAMA increased lung capillary blood volume. Should oxygenation differences persist over time, LAMA could arguably become the first therapeutic choice in COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Olodaterol promotes thermogenesis in brown adipocytes via regulation of the β2-AR/cAMP/PKA signaling pathway. (PubMed, Biochem Biophys Res Commun) - "Furthermore, it promoted brown adipocyte thermogenesis by activating the β2-AR/cAMP/PKA signaling cascades according to RNA sequencing, western blotting, and molecular docking analysis. This investigation underscores the therapeutic potential of OLO for metabolic ailments and sheds light on the intricate molecular dynamics of adipocyte thermogenesis, laying the groundwork for future targeted therapeutic interventions in human metabolic disorders."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study (ACR Convergence 2023) - "Additionally, subjects had to be users of leukotriene inhibitors (montelukast, zafirlukast, or zileuton) or an active comparator that consisted of long-acting beta agonists (albuterol, arformoterol, formoterol, indacaterol, olodaterol, salmeterol, terbutaline, or vilanterol) for any duration from the index date up to 6 months after. Users of leukotriene inhibitors undergoing ACL or meniscal surgery may have lower odds of post-traumatic OA compared with users of long-acting beta agonists."

Clinical • HEOR • Real-world • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD (clinicaltrials.gov) - P3 | N=30 | Completed | Sponsor: Erasme University Hospital

New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=843 | Terminated | Sponsor: Università degli Studi di Ferrara | Trial completion date: Mar 2023 ➔ Oct 2022 | Recruiting ➔ Terminated; Contract terminated between AIFA and the Sponsor (University of Ferrara)

Trial completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of inhaled medications using an in vitro human alveolar microphysiological system. (ERS 2022) - "Salbutamol, olodaterol and fluticasone were applied in small-volume liquid doses to the apical side of the insert and measured over time. This is consistent with clinical data that shows higher retention, and therefore longer lasting effects, of these drugs in lung tissue. The alveolar MPS was predictive of compound dynamics in the lung and will be used to analyse pharmacology and toxicity of inhaled compounds in future studies."

Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Ventilation and tissue oxygenation patterns induced by LABA and LAMA in COPD patients (ERS 2022) - "Objectives To compare proximal and peripheral bronchodilation patterns and their impact on gas exchange of long-acting ß2-adrenergics (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium), the mainstay of treatment in COPD...Despite the opposite gradient of their documented receptor density, both drugs caused a similar peripheral obstruction relief which resulted in an increased tissue oxygenation after LAMA only. Our data suggest that this could be associated to an improvement in the pulmonary capillary vascularization induced by LAMA."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches. (PubMed, Comput Struct Biotechnol J) - "naftifine, butalbital (NS3), vinorelbine, epicriptine (NS3/4A), pipecuronium, trimethaphan (NS5A), olodaterol and vemurafenib (NS5B) etc. targeting HCV NS proteins. These potential repurposed drugs may prove useful in antiviral drug development against HCV."

Journal • Gastrointestinal Cancer • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Oncology • Solid Tumor

Anti-Interleukin-5 Therapy in Patients with Asthma and Chronic Obstructive Pulmonary Disease Overlap: A Single-Center Review (ATS 2022) - "Analysis of variance was performed for the comparison of mean results. 13 ACO patients (54% female) were prescribed an anti-IL-5 medication for at least one year (10 mepolizumab; 3 benralizumab)...All subjects were on high-dose ICS (10 budesonide; 2 mometasone; 1 ciclesonide), a long-acting β-agonist (12 formoterol; 1 olodaterol), and a long-acting muscarinic antagonist (11 tiotropium; 2 umeclidinium)... Anti-IL-5 therapy can be highly beneficial for ACO patients with recurrent exacerbations and elevated blood eosinophils. The role of anti-IL-5 medications should be further explored with a large study in such patients."

Clinical • Review • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • IL5

"I don’t believe there is interaction w/ olodaterol or formoterol. See https://t.co/JmlyMWoDdL" (@JLimHospMD)

Cardiovascular Events and All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Using Olodaterol and Other Long-Acting Beta2-Agonists. (PubMed, Pharmacoepidemiol Drug Saf) - "Olodaterol users had a similar risk for cardiac arrhythmias or myocardial ischaemia as other LABA users. The observed excess all-cause mortality associated with olodaterol use could be due to uncontrolled channelling bias."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4; N=1032; Recruiting; Sponsor: Università degli Studi di Ferrara; Trial completion date: Mar 2022 ➔ Mar 2023; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

8-Hydroxyquinolin-2(1H)-one analogues as potential β-agonists: Design, synthesis and activity study. (PubMed, Eur J Med Chem) - "They behaved as partial β-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β-agonists with potential applicability in chronic respiratory diseases."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. (PubMed, J Manag Care Spec Pharm) - "OBJECTIVE: To compare chronic obstructive pulmonary disease (COPD)-related and all-cause health care resource utilization (HCRU) and costs between COPD patients initiating tiotropium (TIO) + olodaterol (OLO) versus (a) other LAMA + LABA FDCs and (b) umeclidinium (UMEC) + vilanterol (VI), specifically. The authors received no direct compensation related to the development of the manuscript. Part of the results of this study were accepted and presented at the 30th European Respiratory Society (ERS) International Congress (September 7-9, 2020; virtual)."

Clinical • HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells. (PubMed, Respir Res) - "Olodaterol exhibits inherent anti-inflammatory properties on the airway epithelium, in addition to its bronchodilation properties, that is mediated through the β2-adrenergic receptor and independent of ICS usage."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists (clinicaltrials.gov) - P=N/A; N=65406; Completed; Sponsor: Boehringer Ingelheim; N=139885 ➔ 65406

Clinical • Enrollment change • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Inhaled long-acting bronchodilators with or without inhaled glucocorticosteroids for preventing hospitalizations and death in elderly patients with chronic obstructive pulmonary disease. Broncodilatatori inalatori a lunga durata d’ azione con o senza glucocorticosteroidi inalatori nella prevenzione della re-ospedalizzazione e/o della mortalità in pazienti anziani affetti da malattia cronica... (clinicaltrialsregister.eu) - P4; N=1032; Ongoing; Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA

Clinical • New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. (PubMed, J Exp Pharmacol) - "Three ULABAs, indacaterol, olodaterol, and vilanterol, are approved for clinical treatment of COPD. The three approved ULABAs are being combined with antimuscarinic agents and corticosteroids as dual and triple agent treatments that are being tested for clinical use and efficacy. Increasingly, these clinical trials are using specific COPD clinical characteristics to define study populations and to begin to develop therapies that are trait-specific."

Journal • Review • Chronic Obstructive Pulmonary Disease • Developmental Disorders • Immunology • Respiratory Diseases

No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study. (PubMed, Sci Rep) - "The remaining new users of olodaterol and indacaterol were classified as potential off-label users, with prevalence ranging from 17.3% to 48.6% for olodaterol and from 20.5% to 66.6% for indacaterol. This study provides no evidence of a major concern in Europe for olodaterol or indacaterol for off-label use in asthma or for pediatric use."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pediatrics • Respiratory Diseases

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists (clinicaltrials.gov) - P=N/A; N=139885; Completed; Sponsor: Boehringer Ingelheim; Trial completion date: Jul 2020 ➔ Feb 2020; Trial primary completion date: Jul 2020 ➔ Feb 2020

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases